MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SNDX had $8,172K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$8,172K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-60,715 -156,693
Depreciation
3 0
Accretion of investments
2,413 6,810
Non-cash operating lease expense
158 393
Stock-based compensation
12,082 24,167
Amortization of debt issuance costs
62 167
Provision for credit losses
3,667 -
Accounts receivable
5,949 11,852
Inventory
7,183 17,107
Prepaid expenses and other assets
4,364 4,778
Collaboration (payable) receivable, net
-3,420 -31,547
Other receivable
38 -6
Other assets
0 -
Accounts payable
-3,527 5,727
Accrued expenses and other liabilities
1,102 15,370
Net cash used in operating activities
-70,535 -182,957
Purchases of property and equipment
131 -
Purchases of short and long-term investments
30,440 102,251
Proceeds from sales and maturities of short-term investments
103,000 238,280
Net cash provided by investing activities
72,429 136,029
Proceeds from employee stock purchase plan
-80 1,013
Proceeds from stock option exercises
6,358 468
Net cash provided by financing activities
6,278 1,481
Net decrease cash, cash equivalents and restricted cash
8,172 -45,447
Cash and cash equivalents at beginning of period
154,300 -
Cash and cash equivalents at end of period
117,025 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Syndax Pharmaceuticals Inc (SNDX)

Syndax Pharmaceuticals Inc (SNDX)